E. R. Lawlor and P. H. Sorensen, Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?, Crit Rev Oncog, vol.20, pp.155-171, 2015.

N. J. Balamuth and R. B. Womer, Ewing's sarcoma, Lancet Oncol, vol.11, pp.184-192, 2010.

N. Esiashvili, M. Goodman, and R. B. Marcus, Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data, J. Pediatr. Hematol. Oncol, vol.30, pp.425-430, 2008.

N. Gaspar, Ewing Sarcoma: Current Management and Future Approaches Through Collaboration, J. Clin. Oncol, vol.33, pp.3036-3046, 2015.

L. Mascarenhas, Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group, Pediatr Blood Cancer, vol.63, pp.493-498, 2016.

,. Le-deley, Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial, J. Clin. Oncol, vol.32, pp.2440-2448, 2014.

R. B. Womer, Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group, J. Clin. Oncol, vol.30, pp.4148-4154, 2012.

H. E. Grier, Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone, N. Engl. J. Med, vol.348, pp.694-701, 2003.

E. E. Karski, K. K. Matthay, J. M. Neuhaus, R. E. Goldsby, and S. G. Dubois, Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis, Cancer Epidemiol, vol.37, pp.29-33, 2013.

G. Bacci, Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years, Cancer, vol.109, pp.780-786, 2007.

O. Kaidar-person, N. Haim, and G. Bar-sela, Treatment of adult patients with Ewing's sarcoma: compliance with chemotherapy protocols & toxicity, Med. Oncol, vol.28, issue.1, pp.685-689, 2011.

S. Pieper, Ewing's tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International, Clinical Trials EICESS, vol.92, pp.657-663, 2008.

K. Fizazi, Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients, J. Clin. Oncol, vol.16, pp.3736-3743, 1998.

S. K. Ahmed, S. I. Robinson, S. H. Okuno, P. S. Rose, and N. N. Laack, Adult ewing sarcoma: survival and local control outcomes in 102 patients with localized disease, Sarcoma, vol.2013, p.681425, 2013.

R. D. Siegel, L. M. Ryan, and K. H. Antman, Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute, Am. J. Clin. Oncol, vol.11, pp.614-617, 1988.

E. H. Baldini, Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome, Ann. Surg, vol.230, pp.79-86, 1999.

G. Bar-sela, A. Peer, S. Rothschild, and N. Haim, Treatment of patients aged over 50 years with non-osseous Ewing's sarcoma family tumors: five cases and review of literature, Tumori, vol.94, pp.809-812, 2008.

A. A. Gupta, Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy, Cancer, vol.116, pp.3189-3194, 2010.

R. Diaz-beveridge, Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience, J. Pediatr. Hematol. Oncol, vol.37, pp.278-284, 2015.

S. J. Cotterill, Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group, J. Clin. Oncol, vol.18, pp.3108-3114, 2000.

K. R. Duchman, Y. Gao, and B. J. Miller, Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database, Cancer Epidemiol, vol.39, pp.189-195, 2015.

E. E. Karski, Identification of Discrete Prognostic Groups in Ewing Sarcoma, Pediatr Blood Cancer, vol.63, pp.47-53, 2016.

J. Lee, B. H. Hoang, A. Ziogas, and J. A. Zell, Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry, Cancer, vol.116, pp.1964-1973, 2010.

P. Lagarde, Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas, J. Clin. Oncol, vol.31, pp.608-615, 2013.

J. A. Ludwig, Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future, Curr Opin Oncol, vol.20, pp.412-418, 2008.

M. A. Applebaum, Clinical features and outcomes in patients with extraskeletal Ewing sarcoma, Cancer, vol.117, pp.3027-3032, 2011.

M. Castex, Extraosseous localized ewing tumors: improved outcome with anthracyclines-the French society of pediatric oncology and international society of pediatric oncology, J. Clin. Oncol, vol.25, pp.1176-1182, 2007.

T. Cash, Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group, Pediatr Blood Cancer, 2016.

R. Scientific, , vol.7, 2017.

L. M. Barker, T. W. Pendergrass, J. E. Sanders, and D. S. Hawkins, Survival after recurrence of Ewing's sarcoma family of tumors, J. Clin. Oncol, vol.23, pp.4354-4362, 2005.

S. Ferrari, Post-relapse survival in patients with Ewing sarcoma, Pediatr Blood Cancer, vol.62, pp.994-999, 2015.

R. Ladenstein, Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial, J. Clin. Oncol, vol.28, pp.3284-3291, 2010.

U. Dirksen, M. C. Le-deley, B. Brennan, and I. R. Judson, Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul), J. Clin. Oncol, vol.34

M. Paulussen, Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients, J. Clin. Oncol, vol.26, pp.4385-4393, 2008.

S. Loschi, Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults, Bone Marrow Transplant, vol.50, pp.1083-1088, 2015.

K. Jahnukainen, P. Kallio, A. Koivusalo, and U. M. Saarinen-pihkala, High-dose Thiotepa as Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation for High-risk Ewing Family Tumors: Single-institution Experience, J. Pediatr. Hematol. Oncol, vol.37, pp.536-542, 2015.

J. Whelan, M. C. Le-deley, U. Dirksen, I. R. Judson, and D. S. Hawkins, Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial

, J. Clin. Oncol, vol.34

C. Juergens, Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial, Pediatr Blood Cancer, vol.47, pp.22-29, 2006.

M. Vlenterie, Age as an independent prognostic factor for survival of localised synovial sarcoma patients, Br. J. Cancer, vol.113, pp.1602-1606, 2015.

L. G. Sand, K. Szuhai, and P. C. Hogendoorn, Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes, Int J Mol Sci, vol.16, pp.16176-16215, 2015.

F. Tirode, Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations, Cancer Discov, vol.4, pp.1342-1353, 2014.